Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Sees Significant Decline in Short Interest

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totaling 4,487 shares, a decrease of 25.3% from the December 31st total of 6,009 shares. Based on an average daily trading volume, of 13,077 shares, the short-interest ratio is currently 0.3 days. Approximately 0.4% of the company’s stock are sold short. Approximately 0.4% of the company’s stock are sold short. Based on an average daily trading volume, of 13,077 shares, the short-interest ratio is currently 0.3 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Addex Therapeutics in a research note on Friday, January 9th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Addex Therapeutics presently has a consensus rating of “Sell”.

Addex Therapeutics Price Performance

ADXN stock opened at $7.77 on Friday. The company has a market cap of $9.55 million, a price-to-earnings ratio of -1.35 and a beta of 1.49. The company has a fifty day moving average price of $7.95 and a 200 day moving average price of $8.43. Addex Therapeutics has a 12 month low of $6.51 and a 12 month high of $12.05.

Addex Therapeutics (NASDAQ:ADXN) last issued its quarterly earnings data on Thursday, December 4th. The company reported ($1.51) earnings per share (EPS) for the quarter. The business had revenue of $0.04 million for the quarter.

About Addex Therapeutics

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.